Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Up 66.7% in October

Akari Therapeutics PLC (NASDAQ:AKTX) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 248,000 shares, an increase of 66.7% from the September 30th total of 148,800 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 200,400 shares, the days-to-cover ratio is currently 1.2 days. Based on an average trading volume of 200,400 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.8% of the shares of the company are short sold.

Akari Therapeutics Stock Performance

Shares of AKTX stock opened at $0.75 on Friday. The firm’s 50 day moving average is $0.85 and its 200 day moving average is $1.07. Akari Therapeutics has a 12 month low of $0.57 and a 12 month high of $3.15.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AKTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $1.60 target price on shares of Akari Therapeutics in a research note on Tuesday, September 9th. Finally, Maxim Group initiated coverage on shares of Akari Therapeutics in a research note on Friday, July 18th. They issued a “buy” rating and a $5.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.30.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.